Physician profile
Ivan A Hernandez
NPI 1942350236
$1,273.28
in general payments reported to CMS, 2019-2025
9 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $155 · 2021: $137 · 2022: $82.23 · 2023: $153 · 2024: $177 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $322.15 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $267.62 | 2019-2022 | |
| Alkermes, INC. | $168.22 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $129.41 | 2019-2024 | Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $103.27 | 2019-2025 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $90.90 | 2024-2025 | Cobenfy |
| Abbvie INC. | $71.35 | 2021 | |
| Indivior INC. | $67.26 | 2023-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $53.10 | 2019-2023 | Austedo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.